Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares. The reporting period covers the month of September 2025, with the specific transaction date being September 8, 2025. The filing serves as a disclosure of share repurchases executed under a pre-existing non-discretionary agreement with Merrill Lynch International.
Key Financial Metrics and Transaction Details
The filing details a specific block of share repurchases rather than full financial statements. Key metrics for the transaction on September 8, 2025, include:
- Shares Purchased: 219,116 ordinary shares of 31½ pence each.
- Price Range: Lowest price paid was 1,446.00 GBp; highest price paid was 1,485.50 GBp.
- Average Price: Volume-weighted average price paid was 1,460.93 GBp.
- Trading Venue: All purchases occurred on the London Stock Exchange (XLON).
- Cumulative Program Activity: Since the program inception on June 4, 2025, the Company has purchased 27,811,293 ordinary shares.
- Treasury Holdings: Following this purchase, GSK holds 245,945,676 ordinary shares in treasury.
- Shares in Issue: 4,069,456,051 ordinary shares (excluding Treasury shares).
- Voting Rights: Treasury shares represent 6.04% of the total voting rights.
Material Changes and Program Status
The filing confirms the continuation of GSK's existing share buyback program. There are no material changes to the program's structure, which operates under a non-discretionary agreement entered into on June 4, 2025. The purchased shares are being held as Treasury shares. The filing does not provide data on revenue, profit, cash flow, or debt levels, as it is strictly a transaction report.
Guidance, Outlook, and Risks
The filing contains a standard cautionary statement regarding forward-looking statements. GSK notes that projections are subject to risks and uncertainties that may cause actual results to differ materially. Specific risk factors are referenced in GSK's Annual Report on Form 20-F for 2024 and its Q2 Results for 2025. No new guidance or management commentary regarding operational outlook is provided in this specific document.
Important Facts for Investor Verification
- Verify the total number of shares purchased under the buyback program since June 4, 2025 (27,811,293 shares).
- Confirm the current percentage of voting rights held in treasury (6.04%) for disclosure threshold calculations under FCA rules.
- Note that the buyback is executed via a non-discretionary agreement with Merrill Lynch International.
- Review the referenced 2024 Form 20-F and 2025 Q2 Results for detailed risk factors and broader financial performance not included in this transaction report.